Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (NASDAQ: IVVD) Securities Fraud Class Action

Case Background:

A class action lawsuit has been filed on behalf of those who purchased or acquired Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. (“Invivyd”) (NASDAQ: IVVD) common stock between November 29, 2021 and December 14, 2021, both dates inclusive (the “Class Period”). 

The complaint alleges that, throughout the Class Period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) the published epitope mapping, structural studies, and sequence analyses which Defendants had used to claim that ADG20, an investigational monoclonal antibody treatment for COVID-19, was effective against Omicron were insufficient, unreliable, and inadequate to make claims of effectiveness of ADG20 against Omicron; (2) Defendants' claims regarding ADG20's efficacy against Omicron lacked a reasonable factual basis; and (3) ADG20 was over 300 times less effective against the Omicron variant as compared to its effectiveness against previous variants.

Current Status of Case:

On June 28, 2023, the Court appointed Lead Plaintiffs and Lead Counsel.  On November 22, 2023, Lead Plaintiffs filed an amended complaint. On January 12, 2024, Defendants filed a Motion to Dismiss the complaint.  This action is ongoing.   

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Kessler Topaz Meltzer & Check, LLP:  Jonathan Naji, Esq. (484) 270-1453 or via e-mail at [email protected].  If you would like additional information about the suit, please click on the link "Submit Your Information" above and fill out the form as promptly as possible.